TY - JOUR TI - The landscape of m1A modification and its posttranscriptional regulatory functions in primary neurons AU - Zhang, Chi AU - Yi, Xianfu AU - Hou, Mengfan AU - Li, Qingyang AU - Li, Xueying AU - Lu, Lu AU - Qi, Enlin AU - Wu, Mingxin AU - Qi, Lin AU - Jian, Huan AU - Qi, Zhangyang AU - Lv, Yigang AU - Kong, Xiaohong AU - Bi, Mingjun AU - Feng, Shiqing AU - Zhou, Hengxing A2 - Yang, Yongliang A2 - Liu, Caigang VL - 12 PY - 2023 DA - 2023/03/07 SP - e85324 C1 - eLife 2023;12:e85324 DO - 10.7554/eLife.85324 UR - https://doi.org/10.7554/eLife.85324 AB - Cerebral ischaemia‒reperfusion injury (IRI), during which neurons undergo oxygen-glucose deprivation/reoxygenation (OGD/R), is a notable pathological process in many neurological diseases. N1-methyladenosine (m1A) is an RNA modification that can affect gene expression and RNA stability. The m1A landscape and potential functions of m1A modification in neurons remain poorly understood. We explored RNA (mRNA, lncRNA, and circRNA) m1A modification in normal and OGD/R-treated mouse neurons and the effect of m1A on diverse RNAs. We investigated the m1A landscape in primary neurons, identified m1A-modified RNAs, and found that OGD/R increased the number of m1A RNAs. m1A modification might also affect the regulatory mechanisms of noncoding RNAs, e.g., lncRNA–RNA binding proteins (RBPs) interactions and circRNA translation. We showed that m1A modification mediates the circRNA/lncRNA‒miRNA–mRNA competing endogenous RNA (ceRNA) mechanism and that 3' untranslated region (3’UTR) modification of mRNAs can hinder miRNA–mRNA binding. Three modification patterns were identified, and genes with different patterns had intrinsic mechanisms with potential m1A-regulatory specificity. Systematic analysis of the m1A landscape in normal and OGD/R neurons lays a critical foundation for understanding RNA modification and provides new perspectives and a theoretical basis for treating and developing drugs for OGD/R pathology-related diseases. KW - epitranscriptomics KW - neuron KW - m1A modification KW - OGD KW - ncRNA JF - eLife SN - 2050-084X PB - eLife Sciences Publications, Ltd ER -